FDA Approves Kedrion’s Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim(r)

Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company’s manufacturing facility in Bolognana, Italy, to produce RYPLAZIM(r). 

Read More